Evidence map›Paper›PMID 40556639›Full record

ArticleFrontiers in digital health2025

Analysis of the level of polypharmacy in patients from an isolated rural area: effect of age, sex, and chronic diseases.

Susana Abdala Kuri, Chaxiraxi Morales, Alexis M Oliva, Adama Peña, Sandra Dévora

Abstract read
In one paragraph

Article in Frontiers in digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Susana Abdala KuriDepartamento de Medicina Física y Farmacología, Facultad de Farmacia, Universidad de La Laguna, Tenerife, Spain.
Chaxiraxi MoralesDepartamento de Medicina Física y Farmacología, Facultad de Farmacia, Universidad de La Laguna, Tenerife, Spain.
Alexis M OlivaDepartamento de Ingeniería Química y Tecnología Farmacéutica, Facultad de Farmacia, Universidad de La Laguna, Tenerife, Spain.
Adama PeñaDepartamento de Medicina Física y Farmacología, Facultad de Farmacia, Universidad de La Laguna, Tenerife, Spain.
Sandra DévoraDepartamento de Medicina Física y Farmacología, Facultad de Farmacia, Universidad de La Laguna, Tenerife, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The increase in life expectancy and the greater number of chronic diseases have led to a greater use of medications. This polypharmacy can cause a greater number of drug-related problems and negative results on the patient's health associated with medication, which is why most health services are focused on solving these problems. Machine learning uses different techniques to generate knowledge in health, one of them is regression, whose model establishes that a prognosis is created from a dependent variable and a series of independent variables. Materials and methods: Data collection was conducted during 2021-2022 in an isolated rural pharmacy. The screening of participants susceptible to being part of the study began at the time of dispensing, verifying that they were part of the personalized dosing system (PDS) service. Results: The study population consisted of 78 participants, predominantly female. The sociodemographic profile was characterized by being female, between 66 and 80 years of age. The number of chronic diseases per participant was 4.25 ± 1.49. During the study phase, a total of 450 drug-related problems (DRPs) were detected, with an average of 5.64 ± 2.69 DRPs per participant. Discussion: Age and the assigned polypharmacy level are the factors that most influence the final polypharmacy level. However, it is necessary to include the variable "chronic diseases" since in some situations it seems to be significant. Conclusion: The factors that most influence the polypharmacy index are patient age and initial polypharmacy level and, to a lesser extent, but no less important, the number of chronic diseases.

Indexed as

DRPNOMpolypharmacyrural areasafety

Identifiers

PMID40556639
PMCPMC12185413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.